Database : MEDLINE
Search on : alopecia and areata [Words]
References found : 3476 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 348 go to page                         

  1 / 3476 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29512186
[Au] Autor:Kinoshita-Ise M; Fukuyama M; Ohyama M
[Ad] Address:Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan.
[Ti] Title:Color-transition sign: A useful trichoscopic finding for differentiating alopecia areata incognita from telogen effluvium.
[So] Source:J Dermatol;, 2018 Mar 06.
[Is] ISSN:1346-8138
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.1111/1346-8138.14274

  2 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29175284
[Au] Autor:Bae JM; Kim M; Lee HH; Kim KJ; Shin H; Ju HJ; Kim GM; Park CJ; Park HJ
[Ad] Address:Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
[Ti] Title:Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study.
[So] Source:J Invest Dermatol;, 2017 Nov 23.
[Is] ISSN:1523-1747
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Anti-tumor necrosis factor-α (anti-TNF) therapy is used to treat a wide range of chronic inflammatory conditions. However, there has been an increasing number of reports of development of vitiligo and alopecia areata secondary to anti-TNF therapy. In this study, we investigated the risks of vitiligo and alopecia areata in patients with ankylosing spondylitis, Crohn's disease, or ulcerative colitis, who were treated with or without anti-TNF therapy using data from the Korean National Health Insurance Claims database from 2007 to 2016. The study comprised 11,442 patients treated with anti-TNF agents (anti-TNF group), and an equal number of age-, sex-, and disease- matched patients treated without anti-TNF agents (unexposed group). Multivariable Cox proportional hazards models were used to compare the risks of vitiligo and alopecia areata between the two groups. A significantly increased risk of vitiligo (hazard ratio = 1.99, 95% confidence interval = 1.06-3.75) was observed in the anti-TNF group compared to the unexposed group (5.9/10,000 person-years vs. 2.5/10,000 person-years). In subgroup analyses, younger patients and those treated with etanercept showed higher risks of vitiligo. The risk of alopecia areata was not significantly different between the two groups. Our results provide insight on the role of cytokine imbalance in the pathogenesis of vitiligo.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 180303
[Lr] Last revision date:180303
[St] Status:Publisher

  3 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29497840
[Au] Autor:Ramot Y; Marzani B; Pinto D; Sorbellini E; Rinaldi F
[Ad] Address:Department of Dermatology, Hadassah-Hebrew University Medical Center, PO Box 12000, 9112001, Jerusalem, Israel. yramot@gmail.com.
[Ti] Title:IL-17 inhibition: is it the long-awaited savior for alopecia areata?
[So] Source:Arch Dermatol Res;, 2018 Mar 01.
[Is] ISSN:1432-069X
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Interleukin-17 (IL-17) has been implicated in the pathogenesis of a large number of inflammatory and autoimmune conditions, including skin disorders such as psoriasis. Recently, much data have accumulated on the possible role of IL-17 in the pathogenesis of alopecia areata (AA). In this review, the available information on the connection between AA and IL-17 is described. While IL-17 levels are consistently reported to be elevated in the serum and lesional skin of AA patients, there is no clear connection between IL-17 levels and disease severity or duration. Some evidence has suggested an association between IL-17 and an early-onset disease, although this awaits further confirmation. While there is enough information to support clinical trials with IL-17-targeted treatments, it is possible that they will be effective only in a subset of AA patients. Further studies are warranted to better delineate the exact role of IL-17 in AA pathogenesis.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:Publisher
[do] DOI:10.1007/s00403-018-1823-y

  4 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29490767
[Au] Autor:Magen E; Chikovani T; Waitman DA; Kahan NR
[Ad] Address:From the Leumit Health Services, Tel-Aviv, Israel.
[Ti] Title:Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria.
[So] Source:Allergy Asthma Proc;39(2):96-102, 2018 Mar 01.
[Is] ISSN:1539-6304
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Epidemiologic studies report that alopecia areata (AA) is related to various atopic and autoimmune diseases. The purpose of this study was to identify clinical characteristics and the prevalence of comorbid conditions in Israeli patients with AA. METHODS: This retrospective, matched, case-control study was based on data from an electronic patient record data base. The patients with an electronically documented diagnosis of AA were included in the AA group. The control group was randomly sampled from the remaining subjects, with a case-to-control ratio of two controls for each case. Comorbidity was compared between the study groups. RESULTS: A total of 1751 subjects (49.4% men and 50.6% women), ages 34.9 ± 17.8 years old, were identified. The control group consisted of 3502 age- and sex-matched subjects. The AA group was characterized by a higher blood eosinophil count (0.39 ± 0.12 cells/mm3) than the control group (0.31 ± 0.14 cells/mm3; p < 0.001). In the AA group, there was a higher prevalence of allergic rhinitis (odds ratio [OR] 2.15 [1.85-2.49]; p < 0.001), asthma (OR 1.57 [1.28-1.93]; p < 0.001), atopic dermatitis (AD) (OR 4.17 [3.18-5.47]; p < 0.001), and food allergy (OR 2.79 [1.58-4.91]; p < 0.001) than in the control group. The prevalence of organ-specific and systemic autoimmune diseases was significantly higher in the AA group than in the control group, with the OR of having any autoimmune disease calculated to be 4.72 (3.99-5.57; p < 0.001). The OR of having chronic spontaneous urticaria (CSU) with AA was 6.15 (4.06-9.32; p < 0.001). In patients with concomitant AA and CSU, allergic rhinitis and AD were more prevalent than in patients with CSU in the control group. CONCLUSION: An estimated prevalence of AA among an Israeli population was ∼0.8%. The novel finding of our study was the high prevalence of food allergy and CSU in patients with AA.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Data-Review
[do] DOI:10.2500/aap.2018.39.4114

  5 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29485831
[Au] Autor:Güngör O; Kirik S; Isikay S; Güngör G; Bílal N
[Ti] Title:Concomitance of Goldenhar Syndrome with Congenital Alopecia Areata.
[So] Source:Genet Couns;27(2):247-9, 2016.
[Is] ISSN:1015-8146
[Cp] Country of publication:Switzerland
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Process

  6 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29451869
[Au] Autor:Huang W; Zhu Y; Qu H
[Ad] Address:Eastern Operating Room, Yantai Yuhuangding Hospital, Yantai, Shandong, China (mainland).
[Ti] Title:Use of an Alternating Inflatable Head Pad inPatients Undergoing Open Heart Surgery.
[So] Source:Med Sci Monit;24:970-976, 2018 Feb 16.
[Is] ISSN:1643-3750
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND Preoperative symptoms like occipital pressure ulcers and alopecia areata (AA) significantly lowered patient quality of life. Therefore, preoperative nursing was in need of investigation. This study aimed to compare effects of an alternating inflatable head pad and a gel pad on occurrence of postoperative pressure ulcers and AA in patients undergoing open heart surgery. MATERIAL AND METHODS This was a prospective study. We allocated randomly 120 patients undergoing surgery (3-7 h) in the Yantai Yuhuangding Hospital affiliated to Qingdao University, China from January to October 2015 to the control (gel head pad) or the experimental (alternating inflatable head pad) group (n=60 per group). The incidence and severity of occipital pressure ulcer were graded by the classification system of the European Pressure Ulcer Advisory Panel (EPUAP). The degree of occipital alopecia was measured by hair pull test. This study used the t test and chi-square analysis. All statistics were analyzed by SPSS 21.0. RESULTS Compared with the control group, there was a significantly lower incidence and severity of occipital pressure ulcer and alopecia in the experimental group (9 cases/60 cases vs. 1 case/60 cases, P<0.01). Moreover, multivariate analysis showed the risk of developing occipital pressure ulcer after surgery was also obviously lower in the experimental group (OR 1.449-120.798; P<0.005). Hair pull test revealed that fewer patients in the experimental group had a hair loss over 10%. CONCLUSIONS The alternating inflatable head pad was effective in reducing the incidence and severity of occipital pressure ulcer and alopecia associated with surgery, which benefited the postoperative nursing and improved patient quality of life.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Process

  7 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29212074
[Au] Autor:Lyakhovitsky A; Gilboa S; Eshkol A; Barzilai A; Baum S
[Ad] Address:Department of Dermatology, Chaim Sheba Medical Center, Tel Aviv University, Sackler School of Medicine, Ramat Gan, Israel.
[Ti] Title:Late-Onset Alopecia Areata: A Retrospective Cohort Study.
[So] Source:Dermatology;233(4):289-294, 2017.
[Is] ISSN:1421-9832
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:BACKGROUND: Alopecia areata is an immune-mediated disease presenting with sudden onset of nonscarring hair loss. Onset is more common earlier in life, and little is known regarding late-onset alopecia areata. OBJECTIVES: To describe the epidemiology, clinical patterns, disease course, and outcome of late-onset alopecia areata in Israeli patients referred to a tertiary medical center. MATERIALS AND METHODS: This retrospective cohort study considered patients whose disease onset occurred at age ≥50 years. Patients were recruited from among all alopecia areata patients visiting a tertiary center between January 2009 and April 2015. RESULTS: Of the 29 people included, 25 (86.2%) were female (female-to-male ratio, 6.2:1). There was a family history of alopecia areata in 17.2%, thyroid disease in 31%, atopic background in 6.9%, and 17/29 (58.6%) reported a significant stressful event. The most common disease pattern was patchy, and disease was mild in the majority of participants. Complete hair regrowth was observed in 82.8% of participants, and 37.9% relapsed. CONCLUSION: Late-onset alopecia areata is characterized by marked female predominance, less extensive disease, and a high incidence of complete hair regrowth.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Process
[do] DOI:10.1159/000481881

  8 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29480935
[Au] Autor:Karanovic S; Harries M; Kaur MR
[Ad] Address:Department of Dermatology, Solihull Hospital, Heart of England NHS Foundation Trust, Lode Lane, B91 2JL, U.K.
[Ti] Title:Diphencyclopropenone (DPCP) for alopecia areata: a UK survey.
[So] Source:Br J Dermatol;, 2018 Feb 26.
[Is] ISSN:1365-2133
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Alopecia areata (AA) is a T-cell mediated autoimmune hair loss condition with an estimated lifetime risk of 1.7%. It is characterized clinically by sudden-onset non-inflammatory hair loss that may occur at any site. The disease course is unpredictable with many patients experiencing spontaneous re-growth along with episodes of further loss. Unfortunately, around a fifth of patients presenting with patchy alopecia will progress to complete scalp (alopecia totalis (AT)) or scalp & body (alopecia universalis (AU)) hair loss from which spontaneous regrowth is rare (<10%). The adverse psychological consequences of AA include high rates of anxiety and depression. This article is protected by copyright. All rights reserved.
[Pt] Publication type:LETTER
[Em] Entry month:1802
[Cu] Class update date: 180226
[Lr] Last revision date:180226
[St] Status:Publisher
[do] DOI:10.1111/bjd.16489

  9 / 3476 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29466675
[Au] Autor:Iorizzo M; Tosti A
[Ad] Address:a Private Dermatology Practice , Bellinzona , Switzerland.
[Ti] Title:Emerging drugs for alopecia areata: JAK inhibitors.
[So] Source:Expert Opin Emerg Drugs;:1-5, 2018 Feb 26.
[Is] ISSN:1744-7623
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Expert opinion: JAK inhibitors represent a promise among alopecia treatments, but further studies are needed on long term safety. There is still no validated dosage for alopecia areata and the vehicles used for topical formulations seem not yet ideal in terms of skin penetration and reduced systemic absorption. Hopefully several studies are ongoing and we hope, in the near future, that JAK inhibitors will become part of the armamentarium to treat alopecia areata patients in terms of safety and costs.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180226
[Lr] Last revision date:180226
[St] Status:Publisher
[do] DOI:10.1080/14728214.2018.1444750

  10 / 3476 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 29469706
[Au] Autor:Salman A; Sarac G; Ergun T
[Ad] Address:Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey. andac.salman@marmara.edu.tr.
[Ti] Title:Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
[So] Source:Dermatol Online J;23(7), 2017 Jul 15.
[Is] ISSN:1087-2108
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Janus kinase inhibitors are emerging treatment alternatives in various immune-mediated diseases including alopecia universalis. Herein, we report a patient with psoriasis and alopecia universalis in whom treatment with tofacitinib led to remission of psoriasis without improvement in alopecia universalis. Despite the promising potential in alopecia areata treatment, research evaluating the efficacy of different Janus kinase inhibitors and possible prognostic factors related with a more favorable response are warranted.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Process


page 1 of 348 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information